BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38175404)

  • 21. [Lymphoplasmacytic lymphoma accompanied by transformed diffuse large B-cell lymphoma with the MYD88
    Kida T; Tanimura A; Ono A; Matsui T; Honma K; Fujita J; Maeda T; Shibayama H; Oritani K; Morii E; Kanakura Y
    Rinsho Ketsueki; 2017; 58(2):155-160. PubMed ID: 28321094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New developments in non-Hodgkin lymphoid malignancies.
    Ganapathi KA; Brown LE; Prakash S; Bhargava P
    Pathology; 2021 Apr; 53(3):349-366. PubMed ID: 33685720
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Vermaat JS; Somers SF; de Wreede LC; Kraan W; de Groen RAL; Schrader AMR; Kerver ED; Scheepstra CG; Berenschot H; Deenik W; Wegman J; Broers R; de Boer JD; Nijland M; van Wezel T; Veelken H; Spaargaren M; Cleven AH; Kersten MJ; Pals ST
    Haematologica; 2020; 105(2):424-434. PubMed ID: 31123031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic Alterations and MYD88
    Jiang S; Qin Y; Gui L; Liu P; Jiang H; Liu B; Yang J; Yang S; He X; Zhou S; Du X; Yi Y; Lin J; Shi Y
    Target Oncol; 2020 Apr; 15(2):221-230. PubMed ID: 32239385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
    Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
    J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
    Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F
    Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841
    [No Abstract]   [Full Text] [Related]  

  • 27. The impact of MYC rearrangements and "double hit" abnormalities in diffuse large B-cell lymphoma.
    Lin P; Medeiros LJ
    Curr Hematol Malig Rep; 2013 Sep; 8(3):243-52. PubMed ID: 23892979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Follicular lymphoma and diffuse large B-cell lymphoma with BCL2 and IRF4 rearrangements in adult patients.
    Yuan J; Liu H; Hu S; Miranda RN; Xu X; Bayerl MG; Artymiuk CJ; Berg H; King RL; Shi M; He R; Viswanatha D; Medeiros LJ; McPhail ED
    Hum Pathol; 2023 Nov; 141():22-29. PubMed ID: 37634651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Molecular genetic features of sporadic Burkitt's lymphoma in children].
    Yang WP; Huang H; Gong LP; Wu Y; Xu HY; Zou Y; Lü BB; Zhong HS; Deng QQ; Xiao Q; Zeng ST; Zhu CD
    Zhonghua Bing Li Xue Za Zhi; 2010 Dec; 39(12):819-24. PubMed ID: 21215097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity.
    Care MA; Cocco M; Laye JP; Barnes N; Huang Y; Wang M; Barrans S; Du M; Jack A; Westhead DR; Doody GM; Tooze RM
    Nucleic Acids Res; 2014 Jul; 42(12):7591-610. PubMed ID: 24875472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The incidence of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in diffuse large B-cell lymphoma].
    Li M; Zhang QL; Zhao W; Huang X; Gong LP; Shi QF; Liu CL; Gao ZF
    Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):124-128. PubMed ID: 33858042
    [No Abstract]   [Full Text] [Related]  

  • 32. MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.
    Nosrati A; Monabati A; Sadeghipour A; Radmanesh F; Safaei A; Movahedinia S
    Ann Hematol; 2019 Jan; 98(1):169-173. PubMed ID: 30306208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BCL2, BCL6, IGH, TP53, and MYC protein expression and gene rearrangements as prognostic markers in diffuse large B-cell lymphoma: a study of 44 Turkish patients.
    Akay OM; Aras BD; Isiksoy S; Toprak C; Mutlu FS; Artan S; Oner U; Gulbas Z
    Cancer Genet; 2014 Mar; 207(3):87-93. PubMed ID: 24674866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ocular adnexal lymphoma: Subtype-specific clinical and genetic features.
    Kirkegaard MK
    Acta Ophthalmol; 2022 Oct; 100 Suppl 270():3-37. PubMed ID: 36196757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pathobiology of primary testicular diffuse large B-cell lymphoma: Implications for novel therapies.
    Twa DDW; Mottok A; Savage KJ; Steidl C
    Blood Rev; 2018 May; 32(3):249-255. PubMed ID: 29289361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: Biopsy analysis of 70 cases from the Slovak Lymphoma Registry.
    Lešková K; Szépe P; Balhárek T; Barthová M; Janáková Ľ; Farkašová A; Plank L
    Neoplasma; 2022 Jul; 69(4):957-964. PubMed ID: 35652622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reclassification of diffuse large B cell lymphoma to large B cell lymphoma with IRF4 rearrangement in an adult population.
    Hesius EAM; van Laar L; Oosterveld M; van Spriel AB; Scheijen B; Leeuwis JW; Marres HAM; Groenen PJTA; Stevens WBC; van der Spek E; van den Brule AJC; Hoevenaars BM; Hebeda KM; van den Brand M
    Histopathology; 2023 Jun; 82(7):1013-1020. PubMed ID: 36779226
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Tourneret A; Alame M; Rigau V; Bauchet L; Fabbro M; De Oliveira L; Cacheux V; Costes V; Lacheretz-Szablewski V
    J Clin Pathol; 2021 Oct; 74(10):650-656. PubMed ID: 32912960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.
    Yan LX; Liu YH; Luo DL; Zhang F; Cheng Y; Luo XL; Xu J; Cheng J; Zhuang HG
    PLoS One; 2014; 9(8):e104068. PubMed ID: 25090026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological features of 49 primary gastrointestinal diffuse large B-cell lymphoma cases; comparison with location, cell-of-origin, and frequency of MYD88 L265P.
    Nagakita K; Takata K; Taniguchi K; Miyata-Takata T; Sato Y; Tari A; Ohnishi N; Noujima-Harada M; Omote S; Nakamura N; Iwamuro M; Maeda Y; Okada H; Tanimoto M; Yoshino T
    Pathol Int; 2016 Aug; 66(8):444-52. PubMed ID: 27439595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.